

Date and Time: 24th October 2012, 10:00 – 16:30

Minutes: DRAFT

Lipid Modification Guideline

Guideline Development Group Meeting 2

Place: Censors Room, Royal College of Physicians
11 St Andrews Place, Regent's Park, London NW1 4LE

- | | | |
|----------------------|----------------------------|----------------------------|
| GDG Present: | Anthony Wierzbicki (Chair) | (Present for notes 1 – 11) |
| | Lindsay Banks | (Present for notes 1 – 11) |
| | Liz Clark | (Present for notes 1 – 11) |
| | Martin Duerden | (Present for notes 1 – 11) |
| | Eleanor Grey | (Present for notes 1 – 11) |
| | Michael Khan | (Present for notes 1 – 11) |
| | Emma McGowan | (Present for notes 1 – 11) |
| | Dermot Neely | (Present for notes 7 – 11) |
| | Nadeem Quershhi | (Present for notes 1 – 11) |
| | Alan Rees | (Present for notes 1 – 11) |
| | David Wald | (Present for notes 7 – 11) |
| NCGC Present: | Angela Cooper | (Present for notes 1 – 11) |
| | Martin Harker | (Present for notes 1 – 11) |
| | Norma O'Flynn | (Present for notes 1 – 11) |
| | Silvia Rabar | (Present for notes 1 – 11) |
| | Lina Gulhane | (Present for notes 8 – 11) |

In attendance:

| | | |
|-------------|--|--|
| NICE Staff: | | |
|-------------|--|--|

Observers:

| | | |
|--|--|--|
| | | |
|--|--|--|

Agenda item

1. **Welcome introductions and apologies**
Anthony Wierzbicki welcomed the group to the second meeting of this GDG and thanked them for their time and commitment to the guideline. Apologies were received from Clifford Middleton, Rajai Ahmad and Alison Richards.

2. **Declaration of Interests**
The Chair asked all GDG members to declare any new relevant conflicts of interest. The group then verbally declared the following new DOIs:

| |
|---|
| Michael Khan. Personal pecuniary interest: Non-executive director silence therapeutics (AIM listed). Only RNA in oncology, no CVD interest or conflicting funding. Advisory board for Amgen on PCSK9 mAb. |
| Alan Rees. |

Agenda item

| |
|---|
| Personal pecuniary interest: Recruit AD board for MSD – focused on ezetimibe. Recruit talk on new drugs in development for Dyslipidaemia. |
| David Wald. Personal non-pecuniary interest: Academic publications. |
| Emma McGowan. Personal non-pecuniary interest: Participated in an education session for GPs on FH. |
| |

3. **Introduction to GRADE methodology**
The Chair introduced Angela Cooper, Senior Research Fellow at NCGC, who gave a presentation on the GRADE methodology, and took questions from the group. The Chair thanked Angela Cooper for her presentation.
4. **Making recommendations and LETR**
The Chair introduced Norma O’Flynn, Clinical Director at NCGC, who gave a presentation on the wording of recommendation and how to link the evidence to recommendations. The Chair thanked Norma O’Flynn for her presentation.
5. **Review question: For adults with and without CVD, what is the clinical and cost effectiveness of anion-exchange resins versus placebo in preventing cardio-vascular disease?**
The Chair introduced Silvia Rabar (Senior Project Manager and Research Fellow at NCGC) and Martin Harker (Health Economist at NCGC) who gave a presentation on the clinical and cost effectiveness of anion-exchange resins, and took questions from the group. The GDG then discussed the clinical questions in relation to this guideline and developed draft recommendations. The Chair thanked Silvia Rabar and Martin Harker for their presentation.
6. **Review question: For adults with and without CVD what is the clinical and cost effectiveness of nicotinic acids versus placebo in preventing cardio-vascular disease?**
The Chair introduced Angela Cooper (Senior Research Fellow at NCGC) and Martin Harker (Health Economist at NCGC) who gave a presentation on the clinical and cost effectiveness of nicotinic acids, and took questions from the group. The GDG then discussed the clinical questions in relation to this guideline and developed draft recommendations. The Chair thanked Angela Cooper and Martin Harker for their presentation.
7. **Review question: For adults without CVD what is the clinical and cost effectiveness of fibrates versus placebo in preventing cardio-vascular disease?**
The Chair introduced Silvia Rabar (Senior Project Manager and Research Fellow at NCGC) and Martin Harker (Health Economist at NCGC) who gave a presentation on the clinical and cost effectiveness of fibrates for primary prevention of cardio-vascular disease, and took questions from the group. The GDG then discussed the clinical questions in relation to this guideline and developed draft recommendations. The Chair thanked Silvia Rabar and Martin Harker for their presentation.
8. **Introduction to statin review strategy**
The Chair introduced Norma O’Flynn, Clinical Director at NCGC, who gave a presentation on how previous guidelines reviewed efficacy of statins. The GDG discussed advantages and disadvantages of different approaches to review of the efficacy of statins.
9. **Health economics plan**
The Chair introduced Martin Harker (Health Economist at NCGC) who gave a presentation on health economic plan and prioritisation. The GDG discussed the economic plan and formed a health economics subgroup.

Agenda item

10. Statins protocols

There was not enough time to complete discussion on this agenda item, and it is carried forward for the next GDG meeting.

11. Summary of next steps and any other business

There were no other businesses to discuss. The Chair closed the meeting and thanked everybody for attending.

Date, time and venue of the next meeting

30th November 2012, 10.00 – 16.00, at NCGC.